Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation

• Published in: The Lancet (British edition) Vol. 354; no. 9191; pp. 1698 - 1699
• Main Authors: Cook, Richard C, Connors, Joseph M, Gascoyne, Randy D, Fradet, Guy, Levy, Robert D
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 13.11.1999; Lancet; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Murine-Derived; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biological and medical sciences; Disease; Drug therapy; Female; Humans; Immunotherapy; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - drug therapy; Lung Transplantation; Lungs; Lymphatic Metastasis; Lymphoma, B-Cell - diagnostic imaging; Lymphoma, B-Cell - drug therapy; Lymphoma, Large B-Cell, Diffuse - diagnostic imaging; Lymphoma, Large B-Cell, Diffuse - drug therapy; Male; Medical sciences; Pharmacology. Drug treatments; Postoperative Complications - diagnostic imaging; Postoperative Complications - drug therapy; Radiography; Remission Induction; Rituximab; Transplants & implants; Canada; North America; America; Case study; Human; Surgery; Treatment efficiency; Immunotherapy; Lymphoproliferative syndrome; Lung; Rituximab; Complication; Malignant hemopathy; Transplantation; Monoclonal antibody
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(99)02058-9

Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD2O monoclonal antibody. Treatment resulted in two complete remissions and one nonresponse.